Trial Profile
Phase II study of gemcitabine and trastuzumab therapy in patients with HER2 [human epidermal growth factor receptor-2] overexpressing metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 11 Sep 2007 Status changed from in progress to completed.
- 27 Jul 2006 Status change
- 28 Oct 2005 New trial record.